Immune-related Adverse Event Clinical Trials

23 clinical trials for Immune-related Adverse Event across international registries, including 11 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Inhaled Budesonide for REcurrence Prevention and Adjuvant THerapy in Checkpoint Inhibitor Pneumonitis — RECRUITING · PHASE2
• Thymosin Alpha 1 Combined With Anti-PD-1 Monoclonal Antibody in Elderly Patients With Advanced Melanoma — RECRUITING · PHASE2
• Early Adalimumab Induction for Immune Checkpoint Inhibitor Associated Inflammatory Arthritis — RECRUITING · PHASE2
• Prophylactic Mesalamine to Prevent Colitis Following Treatment With Ipilimumab/Nivolumab (Ipi/Nivo) — RECRUITING · PHASE2
• Identification of Predictive Biomarkers for Immune-Related Adverse Events (irAEs) in Patients Undergoing Immune CheckPoint Inhibitors (ICPI) Treatment — RECRUITING · NA
• Food Intervention to Reduce Immunotherapy ToXicity — RECRUITING · NA
• Exploring the Treatment Duration of PD-1 Neoadjuvant Therapy in Stage II-III dMMR Rectal Cancer — RECRUITING
• SATELLITE Study (feaSibility sAfeTy Efficacy dostarLimab earLy-stage defIcient endomeTrial cancEr) — RECRUITING · PHASE2
• The Effect of Serum Ferritin in irAE — RECRUITING · NA
• Treatment of Immune-related Adverse Events Refractory to Standard Therapy and Associated Changes in Immunophenotype — RECRUITING
• Fast-Track Cardiovascular Assessment for Suspicion of Cardiovascular Events on Immunecheckpoint Inhibitors — RECRUITING
• Pharmacokinetic Study of Therapeutic Plasma Exchange — NOT_YET_RECRUITING
• Mycophenolate Mofetil w/ Prednisone for Immune Related Hepatitis From Checkpoint Inhibitor Therapy — NOT_YET_RECRUITING · PHASE2
• Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis — ACTIVE_NOT_RECRUITING · PHASE2
• Rheumatic IMmune-Related Adverse Events in Patients Treated With Immune Check Point Inhibitors — COMPLETED
• Impact of Therapeutic Patient Education on the Toxicity of Immune Checkpoint Inhibitors in Oncology — COMPLETED · NA
• Efficacy and Safety of Neoadjuvant Nivolumab Plus SOX Versus Nivolumab Plus FLOT in Patients With HER2-negative Gastric and Gastroesophageal Junction Adenocarcinoma — COMPLETED
• Safety, Virological and Immunological Assessment of the Controlled Dengue Human Infection Model in Dengue-Immune Participants in Thailand (DHIT-Immune) — NOT_YET_RECRUITING · PHASE1
• Extensive CArdioVAscular Characterization and Follow-up of Patients Receiving Immune Checkpoint Inhibitors — TERMINATED · NA
• Immune-Related Adverse Events and Associated Biomarkers in Patients Receiving Cancer Immunotherapy — COMPLETED
• Statins to Prevent Immune Checkpoint Inhibitor-induced PRogression of AtherosLerosis — NOT_YET_RECRUITING · PHASE4
• EXploring Immune-related Adverse Events of Immune checkpoinT Inhibitors Using VigiBase, the WHO Pharmacovigilance Database — COMPLETED
• Hyperpolarized 13C-MRI and Metabolomics for Immune-related Adverse Events — OTHER

Refine this search